Compare HTBK & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HTBK | AQST |
|---|---|---|
| Founded | 1997 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 667.4M | 707.6M |
| IPO Year | 1998 | 2018 |
| Metric | HTBK | AQST |
|---|---|---|
| Price | $12.66 | $3.41 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $12.88 | $8.83 |
| AVG Volume (30 Days) | 794.3K | ★ 6.3M |
| Earning Date | 01-22-2026 | 03-04-2026 |
| Dividend Yield | ★ 4.07% | N/A |
| EPS Growth | ★ 18.01 | N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $195,648,000.00 | $43,397,000.00 |
| Revenue This Year | $5.97 | N/A |
| Revenue Next Year | $6.02 | $43.02 |
| P/E Ratio | $16.41 | ★ N/A |
| Revenue Growth | ★ 14.91 | N/A |
| 52 Week Low | $8.09 | $2.12 |
| 52 Week High | $13.64 | $7.55 |
| Indicator | HTBK | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 53.96 | 27.37 |
| Support Level | $12.63 | $3.17 |
| Resistance Level | $13.64 | $3.55 |
| Average True Range (ATR) | 0.35 | 0.28 |
| MACD | -0.03 | -0.09 |
| Stochastic Oscillator | 33.33 | 7.85 |
Heritage Commerce Corp operates as a bank holding company. The company, through its subsidiary, offers commercial banking services to small and medium-sized businesses and their owners, managers, and employees. It operates through two reportable segments, namely Banking and Factoring. A majority of its revenue is generated from the Banking segment, which provides various loan products, including commercial and industrial loans, commercial real estate loans, construction loans, etc. This segment also focuses on deposit generation on relationship accounts, encompassing non-interest bearing demand, interest bearing demand, money market accounts, certificates of deposit, and savings accounts.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.